Stratipath is happy to announce that one of the most prominent breast oncologists, Professor Jonas Bergh, will be leading the company’s scientific advisory board. As Stratipath is entering the clinical phase with its first-in-class, CE-IVD solution for AI-driven risk profiling, Stratipath breast and at the same time ramping up the research and development efforts for future solutions, the scientific advisory board will play a crucial role in the company’s development.
Stratipath is listed in tech magazine Ny Teknik’s 33-list, which selects the most promising Swedish start-ups each year. The 33-listThe 33-list by the Swedish tech magazine Ny Teknik acknowledges Sweden’s 33 best and most promising technology startup companies with the potential to reach an international market. Altogether Ny Teknik has evaluated over 300 tech companies this year before presenting the 33 winners.
AI-precision oncology pioneers Stratipath have been awarded the Athena Prize, one of Sweden’s most prestigious awards for innovation in health care for the development of their AI-based solution for improved prognostic analysis of breast cancer, using only microscopy images.
”The path from academic research to precision diagnostics in routine health care” Stratipath co-founder is writing an article about Stratipath and the research behind in ”Oncology Sweden”. (Swedish only)
Read the article (in swedish)
The Swedish deep-tech company Stratipath announces its integration with Sectra, one of the most expanding PACS systems for digital pathology
Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, today announced that it has released its integration with international medical imaging IT company Sectra and their digital pathology solution. This means that Sectra users can use Stratipath’s solution Stratipath Breast within an already existing digital pathology workflow. The application is featured in Sectra Amplifier Marketplace and purchased directly from Stratipath.
rognostic risk stratification of breast cancers, Stratipath Breast, is now CE-IVD marked. This paves the way for clinical implementation in the European Union. Based on the analysis of digital histopathology whole slide images, stained with haematoxylin and eosin (H&E) the software provides novel decision support to clinicians and enables precision medicine for more patients.
Vinnova grants SEK 20 million to the Swedish AI Precision Pathology (SwAIPP) consortia to develop and implement AI-based precision diagnostics in cancer care. The consortia consist of Stratipath, Karolinska Institutet, the pathology clinics in the Kalmar, Västmanland and Skåne regions, Microsoft, Roche Diagnostics, Philips, Bröstcancerförbundet, Prevas and Helseplan.
analysis can stratify intermediate-grade breast cancers into low or high grade. This has strong prognostic value and potential to revolutionize breast pathology.
Study shows large variation in biomarkers and grade among Swedish pathology labs calls for AI-supported image analysis
Read the published article
Stratipath is featured in NyTeknik, Sweden’s largest technology news magazine.
Read more at NyTeknik or MSN